Delivered Revenue of
Secured
Commenced Shipment of Customer Approved Production Components from New Morocco Facility
2025 Full Year Revenue Guidance Remains Unchanged, Adjusted EBITDA Margin Range Expanded
“I am pleased with the
First Quarter Highlights
- Secured automotive new business awards totaling
$400 million , including Gentherm’s first lumbar and massage comfort solutions award by a Japanese OEM and a conquest Climate Control Seat award from Volvo. - Product revenues of
$353.9 million decreased 0.6% from$356.0 million in the prior year. Excluding the impact of foreign currency translation, product revenues increased 0.9%, with Automotive increasing 0.8% and Medical increasing 5.9%. - Automotive Climate and Comfort Solutions revenue increased 3.8% year over year, or 5.3% adjusting for the impact of foreign currency translation, outperforming light vehicle production in our relevant markets by more than 300 basis points (based on S&P Global’s mid-April report).
- Gross margin decreased 50 basis points year over year from 24.9% to 24.4%. The decrease was primarily driven by higher freight costs, product mix, and the costs related to our footprint realignment, partially offset by strong net material performance.
- Net (loss) income was
$(0.1) million , a decrease from$14.9 million in the prior year, primarily driven by net unrealized foreign currency losses, a loss on the sale of the former headquarters building, and the decline in gross margin, partially offset by lower restructuring expenses. - Adjusted EBITDA was
$39.3 million , or 11.1% of revenue, a decrease from$43.5 million , or 12.2% of revenue, in the prior year. The decrease was primarily driven by the decline in gross margin and the negative impact of realized foreign exchange. - GAAP diluted (loss) earnings per share was
$(0.00) , compared to$0.47 in the prior year. - Adjusted diluted earnings per share was
$0.51 , compared to$0.62 in the prior year. - Maintained net leverage ~0.5x and liquidity of
~$400 million , both flat year over year.
Presley concluded, “Despite the near-term disruptions, our priorities remain the same. Our focus is scaling our technology, optimizing our operations, and driving efficiencies.
Guidance
The Company’s guidance for full year 2025 is provided below:
- Product revenues between
$1.4 billion and$1.5 billion - Adjusted EBITDA between 11.5% and 13% of product revenues
- Full year effective tax rate between 26% and 29%
- Capital expenditures between
$70 million and$80 million
Guidance assumes:
- Tariffs currently in effect as of today.
- Limited net impact from changes to customer demand schedules to date.
- A reduction in overall industry demand based on S&P Global Mobility’s Light Vehicle Production Forecast from mid-April
- Compared to the mid-February report, our total relevant markets declined 2% from 74.2 to 72.9 million units, with
North America down 7% from 15.1 to 14.0 million units.
- Compared to the mid-February report, our total relevant markets declined 2% from 74.2 to 72.9 million units, with
- EUR to USD exchange rate of
~$1.10 /Euro.
The Company provides various non-GAAP financial measures in this release. See “Use of Non-GAAP Measures” below for additional information, including definitions, usefulness for investors and limitations, as well reconciliations below to the most directly comparable GAAP financial measures.
Conference Call
As previously announced,
A live webcast and one-year archived replay of the call, as well as a copy of the supplemental materials that will be used during the conference call, can be accessed on the Events page of the Investor section of
A telephonic replay will be available approximately two hours after the call until
Investor Contact
investors@gentherm.com
248.308.1702
Media Contact
Melissa Fischer
media@gentherm.com
248.289.9702
About Gentherm
Gentherm (NASDAQ: THRM) is a global market leader of innovative thermal management and pneumatic comfort technologies. Automotive products include Climate Control Seats (CCS®), Climate Control Interiors (CCI™), Lumbar and Massage Comfort Solutions, and Valve Systems. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 14,000 employees in facilities across 13 countries. In 2024, the company recorded annual sales of approximately
Forward-Looking Statements
Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent
- macroeconomic, geopolitical and similar global factors in the cyclical Automotive industry;
- the impact of, and our ability to mitigate the effects of, global economic and trade policies, including increases in duties, tariffs and taxation on the import or export of our products related to
U.S. trade disputes; - increasing
U.S. and global competition, including with non-traditional entrants; - our ability to effectively manage new product launches and research and development, and the market acceptance of such products and technologies;
- the evolution and challenges of the automotive industry towards electric vehicles, autonomous vehicles and mobility on demand services, and related consumer behaviors and preferences;
- our ability to convert automotive new business awards into product revenues;
- the constraints in the supply chain environment, and inflationary and other cost pressures;
- the production levels of our major customers and OEMs in our relevant markets and sudden fluctuations in such production levels;
- our business in
China , which is subject to unique operational, competitive, geopolitical, regulatory and economic risks; - the impact of our global operations, including our global supply chain, operations within
Ukraine , and foreign currency and exchange risk; - our product quality and safety and impact of product safety recalls and alleged defects in products;
- our ability to attract and retain highly skilled employees and wage inflation;
- a tightening labor market, labor shortages or work stoppages impacting us, our customers or our suppliers, such as recent labor strikes among certain OEMs and suppliers;
- our achievement of product cost reductions to offset customer-imposed price reductions or other pricing pressures;
- our ability to execute efforts to optimize our global supply chain and manufacturing footprint, including opening new facilities and transferring production;
- our ability to source, consummate, integrate and achieve planned benefits of strategic acquisitions, investments and, as applicable, exits;
- any security breaches and other disruptions to our information technology networks and systems, as well as privacy, data security and data protection risks, including risks associated with use of artificial intelligence capabilities in our business operations;
- any loss or insolvency of our key customers and OEMs, or key suppliers;
- our ability to project future sales volume based on third-party information, based on which we manage our business;
- the protection of our intellectual property in certain jurisdictions;
- our compliance with global anti-corruption laws and regulations;
- legal and regulatory proceedings and claims involving us or one of our major customers;
- the extensive regulation of our patient temperature management business;
- risks associated with our manufacturing processes;
- the effects of climate change and catastrophic events, as well as regulatory and stakeholder-imposed requirements to address climate change and other sustainability issues;
- our product quality and safety;
- our borrowing availability under our revolving credit facility, as well as ability to access the capital markets, to support our planned growth; and
- our indebtedness and compliance with our debt covenants.
The foregoing risks should be read in conjunction with the Company's reports filed with or furnished to the
Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its strategies or expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Use of Non-GAAP Financial Measures
In addition to the results reported in accordance with GAAP throughout this release, the Company has provided here or elsewhere information regarding: adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”); Adjusted EBITDA margin; adjusted earnings per share (“Adjusted earnings per share” or “Adjusted EPS”); free cash flow; net capital expenditures (“net CAPEX”); Net Debt, liquidity; net leverage ratio (“net leverage”), revenue, segment revenue and product revenue excluding foreign currency translation and other specified gains and losses; and adjusted operating expenses, each a non-GAAP financial measure. The Company defines Adjusted EBITDA as (losses) earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, non-cash stock based compensation expenses, restructuring expenses, net, unrealized currency gain or loss and other gains and losses not reflective of the Company’s ongoing operations and related tax effects. The Company defines Adjusted EBITDA margin as Adjusted EBITDA divided by product revenues. The Company defines Adjusted EPS as earnings adjusted by restructuring expenses, net, unrealized currency gain or loss and other gains and losses not reflective of the Company’s ongoing operations and related tax effects. The Company defines Free Cash Flow as Net cash from operating activities less Purchases of property and equipment. The Company defines net CAPEX as Purchases of property and equipment less Proceeds from the sale of property and equipment. The Company defines Net Debt as the principal amount of all Consolidated Funded Indebtedness (as defined in the Credit Agreement) less cash and cash equivalents. The Company defines liquidity as the sum of cash and cash equivalents and availability under the Company’s revolving line of credit. The Company defines net leverage as Net Debt divided by Adjusted EBITDA for the trailing four fiscal quarters. The Company defines revenue, segment revenue or product revenue excluding foreign currency translation and other specified gains and losses as such revenue, excluding the estimated effects of foreign currency exchange on revenue by translating actual revenue using the prior period foreign currency exchange rates and excluding the other items specified in the reconciliation tables herein. The Company defines adjusted operating expenses as operating expenses excluding related non-cash stock based compensation, restructuring expenses, net, and other losses not reflective of the Company’s ongoing operations.
The Company’s reconciliations are included in this release or can be found in the supplemental materials on the Company’s website.
In evaluating its business, the Company considers and uses Free Cash Flow and Net Debt as supplemental measures of its liquidity and the other non-GAAP financial measures as supplemental measures of its operating performance. Management provides such non-GAAP financial measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis by excluding matters not indicative of the Company’s ongoing operating or liquidity results and therefore enhance the comparability of the Company's results and provide additional information for analyzing trends in the business. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur revenues, expenses, and cash and non-cash obligations that are the same as or similar to some of the adjustments in our presentation of non-GAAP financial measures. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. There also can be no assurance that we will not modify the presentation of our non-GAAP financial measures in the future, and any such modification may be material. Other companies in our industry may define and calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance or liquidity, investors should not consider these non-GAAP measures in isolation, or as a substitute for net income (loss), revenue or other consolidated income statement or cash flow statement data prepared in accordance with GAAP.
Non-GAAP measures referenced in this release and other public communications may include estimates of future Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EPS. The Company has not reconciled the non-GAAP forward-looking guidance included in this release to the most directly comparable GAAP measures because this cannot be done without unreasonable effort due to the variability and low visibility with respect to taxes and non-recurring items, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results.
CONSOLIDATED CONDENSED STATEMENTS OF (LOSS) INCOME (Dollars in thousands, except per share data) (Unaudited) | ||||||||
Three Months Ended | ||||||||
2025 | 2024 | |||||||
Product revenues | $ | 353,854 | $ | 356,015 | ||||
Cost of sales | 267,389 | 267,262 | ||||||
Gross margin | 86,465 | 88,753 | ||||||
Operating expenses: | ||||||||
Net research and development expenses | 24,216 | 22,745 | ||||||
Selling, general and administrative expenses | 38,478 | 40,721 | ||||||
Restructuring expenses, net | 4,514 | 7,238 | ||||||
Loss on sale of land and building, net | 2,196 | — | ||||||
Total operating expenses | 69,404 | 70,704 | ||||||
Operating income | 17,061 | 18,049 | ||||||
Interest expense, net | (3,555 | ) | (3,244 | ) | ||||
Foreign currency (loss) gain | (10,298 | ) | 2,549 | |||||
Other (loss) income | (1,124 | ) | 973 | |||||
Earnings before income tax | 2,084 | 18,327 | ||||||
Income tax expense | 2,212 | 3,542 | ||||||
Net (loss) income | $ | (128 | ) | $ | 14,785 | |||
Basic (loss) earnings per share | $ | (0.00 | ) | $ | 0.47 | |||
Diluted (loss) earnings per share | $ | (0.00 | ) | $ | 0.47 | |||
Weighted average number of shares – basic | 30,779 | 31,544 | ||||||
Weighted average number of shares – diluted | 30,779 | 31,691 | ||||||
REVENUE BY PRODUCT CATEGORY AND RECONCILIATION OF FOREIGN CURRENCY TRANSLATION IMPACT (Dollars in thousands) (Unaudited) | |||||||||||||
Three Months Ended | |||||||||||||
2025 | 2024 | % Change | |||||||||||
Climate Control Seats (a) | $ | 191,153 | $ | 192,049 | (0.5 | ) | % | ||||||
Climate Control Interiors (a) | 45,341 | 44,398 | 2.1 | % | |||||||||
Lumbar and Massage Comfort Solutions | 45,313 | 38,251 | 18.5 | % | |||||||||
Climate and | 7,715 | 4,226 | 82.6 | % | |||||||||
Automotive Climate and Comfort Solutions | 289,522 | 278,924 | 3.8 | % | |||||||||
Valve Systems | 23,173 | 26,625 | (13.0 | ) | % | ||||||||
Other Automotive (a) | 29,179 | 39,089 | (25.4 | ) | % | ||||||||
341,874 | 344,638 | (0.8 | ) | % | |||||||||
Medical segment | 11,980 | 11,377 | 5.3 | % | |||||||||
$ | 353,854 | $ | 356,015 | (0.6 | ) | % | |||||||
Foreign currency translation impact (b) | (5,421 | ) | — | ||||||||||
currency translation impact | $ | 359,275 | $ | 356,015 | 0.9 | % | |||||||
(a) Product categories have been modified, and prior-period amounts have been recast to conform with the current period presentation. Climate Control Seats (CCS) includes CCS Heat (previously Seat Heaters), CCS Vent/CCS Active Cool (previously CCS) and CCS Neck Conditioners (previously included in | |||||||||||||
(b) Foreign currency translation impacts for the Automotive segment and Medical segment were | |||||||||||||
RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED EBITDA AND ADJUSTED EBITDA MARGIN (Dollars in thousands) (Unaudited) | ||||||||
Three Months Ended | ||||||||
2025 | 2024 | |||||||
Net (loss) income | $ | (128 | ) | $ | 14,785 | |||
Add back: | ||||||||
Depreciation and amortization | 12,788 | 13,580 | ||||||
Income tax expense | 2,212 | 3,542 | ||||||
Interest expense, net (a) | 3,555 | 3,244 | ||||||
Adjustments: | ||||||||
Non-cash stock based compensation (b) | 2,597 | 3,797 | ||||||
Restructuring expenses, net | 4,514 | 7,238 | ||||||
Unrealized currency loss (gain) | 9,607 | (1,856 | ) | |||||
Loss on sale of land and building, net | 2,196 | — | ||||||
Leadership transition expenses | 898 | — | ||||||
Non-automotive electronics inventory benefit | — | (1,060 | ) | |||||
Other (c) | 1,102 | 272 | ||||||
Adjusted EBITDA | $ | 39,341 | $ | 43,542 | ||||
Product revenues | $ | 353,854 | $ | 356,015 | ||||
Net (loss) income margin | (0.0 | )% | 4.2 | % | ||||
Adjusted EBITDA margin | 11.1 | % | 12.2 | % | ||||
(a) Includes | ||||||||
(b) Includes operating expenses of | ||||||||
(c) Includes a $1,294 write-down of an equity investment for the three months ended | ||||||||
RECONCILIATION OF NET (LOSS) INCOME TO ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE (Dollars in thousands, except per share data) (Unaudited) | ||||||||
Three Months Ended | ||||||||
2025 | 2024 | |||||||
Net (loss) income | $ | (128 | ) | $ | 14,785 | |||
Non-cash purchase accounting impact | 1,559 | 1,605 | ||||||
Restructuring expenses, net | 4,514 | 7,238 | ||||||
Unrealized currency loss (gain) | 9,607 | (1,856 | ) | |||||
Loss on sale of land and building, net | 2,196 | — | ||||||
Leadership transition expenses | 898 | — | ||||||
Non-automotive electronics inventory benefit | — | (1,060 | ) | |||||
Other | 1,102 | 272 | ||||||
Tax effect of above | (4,131 | ) | (1,397 | ) | ||||
Adjusted net income | $ | 15,617 | $ | 19,587 | ||||
Weighted average shares outstanding: | ||||||||
Basic | 30,779 | 31,544 | ||||||
Diluted | 30,779 | 31,691 | ||||||
(Loss) earnings per share, as reported: | ||||||||
Basic | $ | (0.00 | ) | $ | 0.47 | |||
Diluted | $ | (0.00 | ) | $ | 0.47 | |||
Adjusted earnings per share: | ||||||||
Basic | $ | 0.51 | $ | 0.62 | ||||
Diluted | $ | 0.51 | $ | 0.62 | ||||
CONSOLIDATED CONDENSED BALANCE SHEETS (Dollars in thousands, except share data) (Unaudited) | ||||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 163,142 | $ | 134,134 | ||||
Accounts receivable, net | 284,241 | 258,112 | ||||||
Inventory: | ||||||||
Raw materials | 143,275 | 137,511 | ||||||
Work in process | 21,455 | 19,059 | ||||||
Finished goods | 71,258 | 70,786 | ||||||
Inventory, net | 235,988 | 227,356 | ||||||
Other current assets | 80,673 | 64,413 | ||||||
Total current assets | 764,044 | 684,015 | ||||||
Property and equipment, net | 253,169 | 252,970 | ||||||
102,431 | 99,603 | |||||||
Other intangible assets, net | 56,288 | 57,251 | ||||||
Operating lease right-of-use assets | 57,550 | 43,954 | ||||||
Deferred income tax assets | 75,867 | 75,041 | ||||||
Other non-current assets | 34,897 | 34,722 | ||||||
Total assets | $ | 1,344,246 | $ | 1,247,556 | ||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 243,224 | $ | 226,815 | ||||
Current lease liabilities | 9,535 | 7,517 | ||||||
Current maturities of long-term debt | 138 | 137 | ||||||
Other current liabilities | 100,333 | 105,824 | ||||||
Total current liabilities | 353,230 | 340,293 | ||||||
Long-term debt, less current maturities | 262,034 | 220,064 | ||||||
Non-current lease liabilities | 50,795 | 37,052 | ||||||
Pension benefit obligation | 3,745 | 4,017 | ||||||
Other non-current liabilities | 27,914 | 29,183 | ||||||
Total liabilities | $ | 697,718 | $ | 630,609 | ||||
Shareholders’ equity: | ||||||||
Common Stock: | ||||||||
No par value; 55,000,000 shares authorized 30,859,119 and 30,788,639 issued and outstanding at | 3,446 | 2,049 | ||||||
Paid-in capital | 4,290 | 4,290 | ||||||
Accumulated other comprehensive loss | (56,881 | ) | (85,193 | ) | ||||
Accumulated earnings | 695,673 | 695,801 | ||||||
Total shareholders’ equity | 646,528 | 616,947 | ||||||
Total liabilities and shareholders’ equity | $ | 1,344,246 | $ | 1,247,556 | ||||
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (Dollars in thousands) (Unaudited) | ||||||||
Three Months Ended | ||||||||
2025 | 2024 | |||||||
Operating Activities: | ||||||||
Net (loss) income | $ | (128 | ) | $ | 14,785 | |||
Adjustments to reconcile net (loss) income to net cash used in operating activities: | ||||||||
Depreciation and amortization | 12,931 | 13,818 | ||||||
Deferred income taxes | (2,769 | ) | (184 | ) | ||||
Stock based compensation | 2,621 | 3,789 | ||||||
Loss on disposition of property and equipment | 2,338 | 69 | ||||||
Provisions for inventory | 1,427 | 296 | ||||||
Other | 1,082 | (842 | ) | |||||
Changes in assets and liabilities: | ||||||||
Accounts receivable, net | (22,597 | ) | (14,856 | ) | ||||
Inventory | (6,141 | ) | (16,648 | ) | ||||
Other assets | (27,312 | ) | (29,226 | ) | ||||
Accounts payable | 14,336 | 12,337 | ||||||
Other liabilities | 10,868 | 6,340 | ||||||
Net cash used in operating activities | (13,344 | ) | (10,322 | ) | ||||
Investing Activities: | ||||||||
Purchases of property and equipment | (14,871 | ) | (11,320 | ) | ||||
Proceeds from the sale of property and equipment | 3,743 | 22 | ||||||
Proceeds from deferred purchase price of factored receivables | 744 | 2,732 | ||||||
Cost of technology investments | (150 | ) | (265 | ) | ||||
Net cash used in investing activities | (10,534 | ) | (8,831 | ) | ||||
Financing Activities: | ||||||||
Borrowings on debt | 52,000 | 10,000 | ||||||
Repayments of debt | (10,037 | ) | (10,324 | ) | ||||
Proceeds from the exercise of Common Stock options | — | 812 | ||||||
Taxes withheld and paid on employees' stock based compensation | (1,224 | ) | (2,022 | ) | ||||
Net cash provided by (used in) financing activities | 40,739 | (1,534 | ) | |||||
Foreign currency effect | 12,147 | (3,879 | ) | |||||
Net increase (decrease) in cash and cash equivalents | 29,008 | (24,566 | ) | |||||
Cash and cash equivalents at beginning of period | 134,134 | 149,673 | ||||||
Cash and cash equivalents at end of period | $ | 163,142 | $ | 125,107 | ||||
Supplemental disclosure of cash flow information: | ||||||||
Cash paid for taxes | $ | 5,152 | $ | 4,900 | ||||
Cash paid for interest | 3,128 | 3,310 | ||||||
OTHER NON-GAAP RECONCILIATIONS (Dollars in thousands) (Unaudited) | ||||||||
Three Months Ended | ||||||||
2025 | 2024 | |||||||
Total operating expenses | $ | 69,404 | $ | 70,704 | ||||
Restructuring expense, net | (4,514 | ) | (7,238 | ) | ||||
Non-cash stock based compensation | (2,349 | ) | (3,490 | ) | ||||
Leadership transition expenses | (898 | ) | — | |||||
Loss on sale of land and building, net | (2,196 | ) | — | |||||
Other | — | (840 | ) | |||||
Adjusted operating expenses | $ | 59,447 | $ | 59,136 |
Cash and cash equivalents | $ | 163,142 | $ | 125,107 | ||||
Revolving line of credit availability | 235,224 | 278,000 | ||||||
Total liquidity | $ | 398,366 | $ | 403,107 | ||||

2025 GlobeNewswire, Inc., source